Form 4: Marinus Pharmaceuticals Director Timothy Mayleben Reports Stock and Option Awards

Director Timothy Mayleben reported the acquisition of restricted stock units and stock options in Marinus Pharmaceuticals, Inc.

Summary

• On June 18, 2024, Timothy Mayleben, a director of Marinus Pharmaceuticals, Inc., reported the acquisition of 2,300 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted on June 18, 2024, and will vest in full on July 15, 2025, contingent upon Mayleben's continued service with the company.
• Each RSU represents the right to receive one share of Marinus Pharmaceuticals common stock.
• Mayleben also acquired options to purchase 10,450 shares of common stock at an exercise price of $1.40 per share.
• These options also vest and become exercisable in full on July 15, 2025, subject to continued service, and expire on June 18, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document simply reports standard stock and option grants to a director, which is a common practice.

Positives

• The grant of RSUs and stock options to a director aligns their interests with the long-term success of the company.
• The vesting schedule incentivizes continued service and commitment from the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's prospects.

Stakeholder Impact

• The grant of equity to a director can align their interests with those of shareholders.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Form 4, Timothy Mayleben, Director, Restricted Stock Units, Stock Options, Beneficial Ownership, Securities